NimBio
NimBio

NimBio

NimBio develops non-invasive diagnostic tools for early disease detection using advanced biosensing.

2019Active5San Francisco, United States

About

NimBio offers a proactive care solution for Inflammatory Bowel Disease (IBD) patients through its Inflammometer™ platform, which uses passive biosensing for real-time inflammation monitoring and early flare detection. This platform aims to provide effortless, remote, and personalized care for patients, while enhancing care delivery for hospitals and physicians, optimizing treatment for pharma, and reducing hospitalizations for payers. NimBio's solution focuses on identifying flare causes and offering therapeutic recommendations to prevent complications and optimize IBD management.

Key facts

At-a-glance profile data

Website
nimbio.ai
Headquarters
San Francisco, United States
Founded
2019
Employees
5
Total funding
-
Business model
B2B

Funding rounds

Funding rounds raised by NimBio
DateRoundAmountLead investors
7 Dec 2022Pre-SeedUndisclosedeHealth Ventures

Tech stack

Detected on nimbio.ai, last scanned 7 Sept 2026. Run your own scan

Email provider
Google Workspace
Add first review

Frequently asked

How many employees does NimBio have?

NimBio has approximately 5 people on record.